 Connection
Breelyn Wilky to Sarcoma
This is a "connection" page, showing publications Breelyn Wilky has written about Sarcoma.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
7.303 |
|
|
|
-
Wilky BA, Julian KA, Maleddu A, Mailhot AC, Cartwright CR, Gao D, Moreno Tellez C, Kemp LE, Therrien NR, Chaudhry SS, Rytlewski JD, Brockman QR, Davila E, Elias AD. A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti-CTLA-4 Antibody) and Balstilimab (Anti-PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas. Clin Cancer Res. 2025 Jul 15; 31(14):2945-2956.
Score: 0.751
-
Wilky BA, Schwartz GK, Gordon MS, El-Khoueiry AB, Bullock AJ, Henick B, Agulnik M, Singh A, Mahadevan D, Stebbing J, Delepine C, Chand D, Avagyan M, Wu W, Johnson B, Grossman JE, O'Day S, Trent JC, Jones RL, Tsimberidou AM. Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas. J Clin Oncol. 2025 04 10; 43(11):1358-1368.
Score: 0.727
-
Wilky BA, Lanning RM. Behaving Badly: Thinking Outside the Box for Treatment of Sarcoma in a Challenging Location. Int J Radiat Oncol Biol Phys. 2024 07 15; 119(4):1055-1056.
Score: 0.697
-
Fontebasso AM, Rytlewski JD, Blay JY, Gladdy RA, Wilky BA. Precision Oncology in Soft Tissue Sarcomas and Gastrointestinal Stromal Tumors. Surg Oncol Clin N Am. 2024 04; 33(2):387-408.
Score: 0.677
-
Hall F, Villalobos V, Wilky B. Future directions in soft tissue sarcoma treatment. Curr Probl Cancer. 2019 08; 43(4):300-307.
Score: 0.493
-
Florou V, Wilky BA. Current and Future Directions for Angiosarcoma Therapy. Curr Treat Options Oncol. 2018 03 08; 19(3):14.
Score: 0.451
-
Alavi SN, Florou V, Tinoco G, Trent JC, Wilky BA. A precision medicine approach in sarcoma: identification of patients who may benefit from early use of pazopanib. Discov Med. 2018 03; 25(137):131-144.
Score: 0.450
-
Wilky BA, Goldberg JM. From vision to reality: deploying the immune system for treatment of sarcoma. Discov Med. 2017 01; 23(124):61-74.
Score: 0.416
-
Wilky BA, Jones RL, Keedy VL. The Current Landscape of Early Drug Development for Patients With Sarcoma. Am Soc Clin Oncol Educ Book. 2017; 37:807-810.
Score: 0.416
-
Subhawong TK, Wilky BA. Value added: functional MR imaging in management of bone and soft tissue sarcomas. Curr Opin Oncol. 2015 Jul; 27(4):323-31.
Score: 0.374
-
Wilky BA, Goldberg JM. Immunotherapy in sarcoma: a new frontier. Discov Med. 2014 Apr; 17(94):201-6.
Score: 0.343
-
Wilky BA, Meyer CF, Trent JC. Pazopanib in sarcomas: expanding the PALETTE. Curr Opin Oncol. 2013 Jul; 25(4):373-8.
Score: 0.326
-
Soupir A, Ospina OE, Hampton O, Churchman M, Radmacher M, Hedges D, McKean D, Agius P, Zeeshan S, Seligson ND, Pollock R, Liebner D, Chen JL, Tinoco G, Salhia B, McCarter M, Wilky BA, Miller BJ, Cavnar MJ, Groundland JS, Schneider BP, Riedlinger G, Edge SB, Moskaluk CA, Cardona K, Naqash AR, Gonzalez RJ, Mullinax JE, Joyce DM, Binitie O, Douglas Letson G, Naghavi AO, Druta M, Reed DR, Siegel EM, Teer JK, Fridley BL, Brohl AS. Genomic, transcriptomic, and immunogenomic landscape of over 1300 sarcomas of diverse histology subtypes. Nat Commun. 2025 May 06; 16(1):4206.
Score: 0.185
-
Stacchiotti S, Maria Frezza A, Demetri GD, Blay JY, Bajpai J, Baldi GG, Baldini EH, Benjamin RS, Bonvalot S, Bovée JVMG, Callegaro D, Casali PG, D'Angelo SP, Davis EJ, Dei Tos AP, Demicco EG, Desai J, Dileo P, Eriksson M, Gelderblom H, George S, Gladdy RA, Gounder MM, Gupta AA, Haas R, Hayes A, Hohenberger P, Jones KB, Jones RL, Kasper B, Kawai A, Kirsch DG, Kleinerman ES, Le Cesne A, Maestro R, Martin Broto J, Maki RG, Miah AB, Palmerini E, Patel SR, Raut CP, Razak ARA, Reed DR, Rutkowski P, Sanfilippo RG, Sbaraglia M, Schaefer IM, Strauss DC, Strauss SJ, Tap WD, Thomas DM, Trama A, Trent JC, van der Graaf WTA, van Houdt WJ, von Mehren M, Wilky BA, Fletcher CDM, Gronchi A, Miceli R, Wagner AJ. Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments. Cancer Treat Rev. 2022 Nov; 110:102455.
Score: 0.153
-
Moreno Tellez C, Leyfman Y, D'Angelo SP, Wilky BA, Dufresne A. Immunotherapy in Sarcoma: Where Do Things Stand? Surg Oncol Clin N Am. 2022 07; 31(3):381-397.
Score: 0.152
-
Stacchiotti S, Frezza AM, Blay JY, Baldini EH, Bonvalot S, Bovée JVMG, Callegaro D, Casali PG, Chiang RC, Demetri GD, Demicco EG, Desai J, Eriksson M, Gelderblom H, George S, Gounder MM, Gronchi A, Gupta A, Haas RL, Hayes-Jardon A, Hohenberger P, Jones KB, Jones RL, Kasper B, Kawai A, Kirsch DG, Kleinerman ES, Le Cesne A, Lim J, Chirlaque López MD, Maestro R, Marcos-Gragera R, Martin Broto J, Matsuda T, Mir O, Patel SR, Raut CP, Razak ARA, Reed DR, Rutkowski P, Sanfilippo RG, Sbaraglia M, Schaefer IM, Strauss DC, Sundby Hall K, Tap WD, Thomas DM, van der Graaf WTA, van Houdt WJ, Visser O, von Mehren M, Wagner AJ, Wilky BA, Won YJ, Fletcher CDM, Dei Tos AP, Trama A. Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer. 2021 08 15; 127(16):2934-2942.
Score: 0.140
-
Kerr DA, Pinto A, Subhawong TK, Wilky BA, Schlumbrecht MP, Antonescu CR, Nielsen GP, Rosenberg AE. Pericytoma With t(7;12) and ACTB-GLI1 Fusion: Reevaluation of an Unusual Entity and its Relationship to the Spectrum of GLI1 Fusion-related Neoplasms. Am J Surg Pathol. 2019 12; 43(12):1682-1692.
Score: 0.127
-
Ramey SJ, Yechieli R, Zhao W, Kodiyan J, Asher D, Chinea FM, Patel V, Reis IM, Wang L, Wilky BA, Subhawong T, Trent JC. Limb-sparing surgery plus radiotherapy results in superior survival: an analysis of patients with high-grade, extremity soft-tissue sarcoma from the NCDB and SEER. Cancer Med. 2018 09; 7(9):4228-4239.
Score: 0.116
-
Ezuddin NS, Pretell-Mazzini J, Yechieli RL, Kerr DA, Wilky BA, Subhawong TK. Local recurrence of soft-tissue sarcoma: issues in imaging surveillance strategy. Skeletal Radiol. 2018 Dec; 47(12):1595-1606.
Score: 0.114
-
Sebio A, Wilky BA, Keedy VL, Jones RL. The current landscape of early drug development for patients with sarcoma in the immunotherapy era. Future Oncol. 2018 May; 14(12):1197-1211.
Score: 0.114
-
Thornton KA, Chen AR, Trucco MM, Shah P, Wilky BA, Gul N, Carrera-Haro MA, Ferreira MF, Shafique U, Powell JD, Meyer CF, Loeb DM. A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma. Int J Cancer. 2013 Aug 15; 133(4):997-1005.
Score: 0.080
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|